<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02502409</url>
  </required_header>
  <id_info>
    <org_study_id>B-Natural</org_study_id>
    <nct_id>NCT02502409</nct_id>
  </id_info>
  <brief_title>Natural History Study of Factor IX Treatment and Complications</brief_title>
  <acronym>B-Natural</acronym>
  <official_title>Natural History Study of Factor IX Treatment and Complications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Skane University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Indiana Hemophilia &amp;Thrombosis Center, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bioverativ Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swedish Orphan Biovitrum</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Skane University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine two groups of subjects with factor IX (FIX) deficiency: 1) those with&#xD;
      a current or history of inhibitors to FIX, and; 2) groups of two or more affected brothers,&#xD;
      with or without inhibitors. The overall goal is to characterize the study groups in terms of&#xD;
      their medical history, their patterns of bleeding, their care, quality of life, and&#xD;
      complications including the development of joint disease, inhibitory antibodies to FIX, use&#xD;
      of immune tolerance induction (ITI) and outcome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hemophilia B, FIX deficiency, is the second most common type of hemophilia, occurring in&#xD;
      about one in 25,000 male births. This disease is in some ways more complex than hemophilia A,&#xD;
      and is less well understood. Differences include a lower incidence and a greater risk of side&#xD;
      effects to treatment, for example, allergic reactions and kidney disease. This study will&#xD;
      examine two groups of subjects with FIX deficiency - those with a current or history of&#xD;
      inhibitors to FIX, and groups of two or more affected brothers, with or without inhibitors.&#xD;
      The overall goal is to characterize the study group in terms of their medical history, their&#xD;
      patterns of bleeding, their care, quality of life, and complications including the&#xD;
      development of inhibitory antibodies to FIX, allergies, kidney, and joint disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">June 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Inhibitory antibodies</measure>
    <time_frame>Baseline</time_frame>
    <description>Current or history of inhibitors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Annualized bleeding rate</measure>
    <time_frame>6 months</time_frame>
    <description>Overall and by bleeding site</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Joint assessment</measure>
    <time_frame>Baseline</time_frame>
    <description>Range of motion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal disorders</measure>
    <time_frame>6 months</time_frame>
    <description>Reported subject and family history of renal disease</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemophilia treatment adherence</measure>
    <time_frame>Baseline</time_frame>
    <description>Validated Hemophilia Regimen Treatment Adherence Scale--Prophylaxis (VERITAS-Pro), Validated Hemophilia Regimen Treatment Adherence Scale - PRN (VERITAS-PRN)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health related quality of life</measure>
    <time_frame>Baseline</time_frame>
    <description>European Quality of Life - 5 Dimensions (EQ5D)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-inhibitory antibodies</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured at central laboratory</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Factor IX usage</measure>
    <time_frame>6 months</time_frame>
    <description>Treatment history with FIX replacement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalizations</measure>
    <time_frame>6 months</time_frame>
    <description>Hospitalizations reported during 6 month follow up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of surgical procedures</measure>
    <time_frame>6 months</time_frame>
    <description>Surgical procedures reported during 6 month follow up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of days missed from school or work</measure>
    <time_frame>6 months</time_frame>
    <description>Days missed from school or work during 6 month follow up period</description>
  </secondary_outcome>
  <enrollment type="Anticipated">550</enrollment>
  <condition>Factor IX Deficiency</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard care with blood and urine sample collection</intervention_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, plasma, cells&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The population includes groups of two or more affected brothers, with or without a history&#xD;
        of inhibitors, who share(d) one or both biological parents; and individuals with a history&#xD;
        of an inhibitor. Most affected brother pairs will be concordant for no inhibitor and will&#xD;
        serve as a control group for those with inhibitors. The study is open to subjects with mild&#xD;
        (0.05-0.40 IU/mL), moderate (0.01-&lt;0.05 IU/mL), or severe (&lt;0.01 IU/mL) FIX deficiency.&#xD;
        Females meeting the eligibility criteria may participate. There are no lower or upper age&#xD;
        limits. Type of treatment, regimen, dosing and product(s) used are at the discretion of the&#xD;
        investigator.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. A consent approved by the appropriate Institutional Review Board (IRB)/Independent&#xD;
             Ethics Committee (IEC) has been obtained from the subject or his legally acceptable&#xD;
             representative&#xD;
&#xD;
          2. Subject has FIX deficiency AND&#xD;
&#xD;
               -  Is part of an affected brother pair/group that will also enroll; AND/OR&#xD;
&#xD;
               -  Has a current or history of inhibitor, defined as &gt;0.6 Bethesda units (BU)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has another congenital bleeding disorder&#xD;
&#xD;
          2. Subject is a carrier of hemophilia B with factor level &gt;0.40 IU/mL&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erik Berntorp, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Skåne University Hospital, Malmö</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amy D Shapiro, MD</last_name>
    <role>Study Director</role>
    <affiliation>Indiana Hemophilia &amp;Thrombosis Center, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan Astermark, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Skåne University Hospital, Malmö</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christine Knoll, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Phoenix Children's Hospital, Phoenix, AZ</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yasmina Abajas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina Hemophilia Treatment Center, Chapel Hill, NC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Catherine McGuinn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Cornell Medical College, New York, NY</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Munira Borhany, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Blood Disease and Bone Marrow Transplantation, Karachi, Pakistan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philip Kuriakose, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henry Ford Health System, Detroit, MI</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eva Funding, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National University Hospital Copenhagen, Copenhagen, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stacy Croteau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Hemophilia Center, Boston, MA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christine Kempton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University, Atlanta, Georgia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susan Kearney, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospitals and Clinics of Minnesota, Minneapolis, MN</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Suchitra Acharya, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cohen Children's Medical Center, New Hyde Park, NY</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roshni Kulkarni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Michigan State University, East Lansing, MI</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raina Liesner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Great Ormond Street Hospital for Children, London, UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christoph Bidlingmaier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dr. v Hauner Children's University Hospital, Munich, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alice J. Cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Newark Beth Israel Medical Center, Newark, NJ</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manuela Carvalho, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Hospitalar de São João, Porto, Portugal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Margaret Ragni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh and Hemophilia Center of Western Pennsylvania, Pittburgh, PA US</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulrike Reiss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Jude Children's Research Hospital, Memphis, TN US</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michelle Witkop, DNP, FNP-BC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Munson Medical Center, Traverse City, MI, US</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Katharina Holstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Centre Hamburg-Eppendorf, Hamburg, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cristina Tarango, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cincinnati Children's Hospital Medical Center, Cincinnati, OH US</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael D Tarantino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bleeding and Clotting Disorders Institute, Peoria, IL US</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Johannes Oldenburg, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Clinic, Bonn</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana Hemophilia &amp; Thrombosis Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Sweden</country>
  </removed_countries>
  <reference>
    <citation>Shapiro AD, Ragni MV, Borhany M, Abajas YL, Tarantino MD, Holstein K, Croteau SE, Liesner R, Tarango C, Carvalho M, McGuinn C, Funding E, Kempton CL, Bidlingmaier C, Cohen A, Oldenburg J, Kearney S, Knoll C, Kuriakose P, Acharya S, Reiss UM, Kulkarni R, Witkop M, Lethagen S, Donfield S, LeBeau P, Berntorp E, Astermark J. Natural history study of factor IX deficiency with focus on treatment and complications (B-Natural). Haemophilia. 2021 Jan;27(1):49-59. doi: 10.1111/hae.14139. Epub 2020 Dec 5.</citation>
    <PMID>33278853</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 13, 2015</study_first_submitted>
  <study_first_submitted_qc>July 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2015</study_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Skane University Hospital</investigator_affiliation>
    <investigator_full_name>Sharyne M. Donfield, Ph.D.</investigator_full_name>
    <investigator_title>Principal Investigator, Data Coordinating Center, Rho, Inc.</investigator_title>
  </responsible_party>
  <keyword>Hemophilia B</keyword>
  <keyword>Hemophilia B with Inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia B</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

